The development of a new tuberculosis (TB) vaccine has been an active area of research and investment. TB is a bacterial infection caused by Mycobacterium tuberculosis, and while the Bacille Calmette-Guérin (BCG) vaccine is currently used for TB prevention, there is ongoing research to develop more effective vaccines.
Latest Tuberculosis Vaccine Treatment Companies Updates:
GSK Following the positive Phase 3 trial results for M72/AS01E, GSK is gearing up for regulatory submissions and expects potential market launch in the coming years.
Serum Institute of India This Indian biotech giant is developing its own TB vaccine candidate, with plans to enter Phase 3 trials soon.
Hi-Tech Medical International This Australian company is exploring a novel DNA-based vaccine approach for TB prevention.
List of Tuberculosis Vaccine Treatment Key companies in the market:
Tuberculosis Vaccine Treatment Market Scenario:
The tuberculosis vaccine treatment market is projected to reach USD 80.08 Million by 2030 at 5.67% CAGR during the forecast period 2022-2030.Tuberculosis (TB) is an infectious disease which is caused by the bacteria called Mycobacterium tuberculosis (MTB). Tuberculosis mainly affects lungs, but can also affect other parts of the body. Typical signs of tuberculosis includes chronic or persistent cough and sputum production. When TB is at an advanced stage the sputum will contain blood and other symptoms include lack of appetite, weight loss, fever, and night sweats.
 The vaccines trigger a potent immune response against infectious diseases; tuberculosis (TB) vaccines prevent infection with tuberculosis. Robert Koch was first to propose immunotherapy as a defense mechanism against TB. Currently, the only effective tuberculosis vaccine is BCG (Bacilli Calmette-Guerin).
Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of the Tuberculosis Vaccine Treatment Market. Furthermore, improving healthcare infrastructure and emphasis on prevention of diseases drive the growth of Tuberculosis Vaccine Treatment Market.
According to Centers for disease control and prevention, One third of the world’s population is infected with TB. In 2016, 10.4 million people around the world became sick with TB disease. There were 1.7 million TB-related deaths worldwide. A total of 9,272 TB cases (a rate of 2.9 cases per 100,000 persons) were reported in the United States in 2016.
However, on the other hand, side effects occurring from the vaccinations and the government approval time for the vaccine are the major factors that may hinder the growth of the Tuberculosis Vaccine Treatment Market.
Intended Audience
Figure 1- Tuberculosis vaccine treatment market, by type of TB test 
   Annual reports, press release, white paper, company presentationÂ
Segmentation
Tuberculosis vaccine treatment market is segmented on the basis of types of test, type of TB vaccines, and end users.
On the basis of type of test, it is segmented into tuberculin skin test (TST), TB blood tests, IGRAs (interferon-gamma release assays), and others.
On the basis of type of Tb vaccines, it is segmented into immunotherapeutic vaccines, booster vaccines, and others.
And on the basis of end users, it is segmented into hospitals, private clinics, research institutes, and others. Â
Regional Analysis On the regional basis, the tuberculosis vaccine treatment market is segmented into America, Europe, Asia Pacific and the Middle East & Africa.
America holds the largest market share of TB vaccines due to the major market players are concentrated and its emphasis on vaccination against TB.
Europe accounts for the second largest market for TB vaccines; this is due to increase in research and development activities by research institutions and pharmaceutical companies. According to UK TB statistics reports, in 2016 there were 5,664 TB cases 39% of cases were in diagnosed in London and 3.8% of people with TB were also living with HIV.
Asia Pacific is expected to be the fastest growing market for Tuberculosis vaccines market over the forecast period. India and China are expected to be emerging and fastest growing countries in this regional market.
According to WHO, India accounts with the highest burden of TB. In 2015, an estimated incidence of 2.84 million cases of TB in India.
On the other hand, The Middle East and Africa holds least market share due to limited screening, ignorance of diseases, and poor access to treatment.
Key Players Merck & Co., Inc.(US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), GlaxoSmithKline plc (UK), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(US), Solvay(US), Informa plc.(US) and others.Â
Market Assessment
Annual reports, World Health Organization (WHO), white paper, company presentation
Tuberculosis Vaccine Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)